ECHS1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the ECHS1 gene has been disrupted to abolish expression of mitochondrial short-chain enoyl-CoA hydratase. This polyclonal knockout model, derived from the HT29 human colorectal adenocarcinoma cell line, is generated without single-cell cloning and provides a heterogeneous loss-of-function system suitable for studying the consequences of ECHS1 deficiency in a cancer-relevant epithelial background. The CRISPR/Cas9-mediated gene disruption eliminates ECHS1 enzymatic activity, enabling researchers to interrogate the role of mitochondrial fatty acid ??-oxidation and branched-chain amino acid catabolism in cellular metabolism and disease.
The HT29 host cell line is a widely used human colorectal adenocarcinoma model with epithelial morphology, originally isolated from a primary colon tumor. HT29 cells retain many characteristics of colon carcinoma, including the ability to differentiate under specific culture conditions, and are frequently employed in cancer biology, drug discovery, and metabolic research. Their robust growth and well-characterized signaling networks make them an appropriate chassis for investigating how mitochondrial metabolic enzymes impact tumor cell proliferation, survival, and metabolic adaptation. The polyclonal nature of this knockout population helps maintain genetic heterogeneity that may better recapitulate the complexity of tumor cell populations compared to monoclonal derivatives.
ECHS1 encodes the short-chain enoyl-CoA hydratase, a key enzyme in the mitochondrial fatty acid ??-oxidation spiral. It catalyzes the stereospecific hydration of trans-2-enoyl-CoA thioesters of C4?CC6 chain length to L-3-hydroxyacyl-CoA intermediates, a step that occurs downstream of ACADVL-catalyzed dehydrogenation and upstream of HADHA/HADHB-mediated processing. ECHS1 functions as part of the trifunctional protein complex, physically interacting with HADHA, HADHB, and ACAA2, and also forms homodimers. Its expression is transcriptionally regulated by PPAR?? and PGC-1?? in concert with retinoid X receptor alpha, and is induced under fasting or high-fat dietary conditions. The reaction catalyzed by ECHS1 feeds substrates into the later steps of ??-oxidation and the TCA cycle, yielding acetyl-CoA, NADH, and FADH2, thereby directly impacting mitochondrial ATP production and ketone body synthesis.
In the context of HT29 cells, ECHS1 knockout disrupts the terminal steps of short-chain fatty acid oxidation and branched-chain amino acid degradation, leading to metabolic reprogramming characteristic of mitochondrial dysfunction. The loss of ECHS1 causes accumulation of enoyl-CoA species and shortage of TCA cycle intermediates, reducing NADH and FADH2 supply to the electron transport chain, lowering ATP synthesis, and increasing oxidative stress. These alterations can impair proliferation, particularly under glucose-limited conditions where HT29 cells may rely on fatty acid oxidation for energy and anabolic precursors. The polyclonal knockout model thus serves as a valuable tool to dissect how colon cancer cells adapt their metabolism when mitochondrial ??-oxidation is compromised, and to identify vulnerabilities that may be exploited therapeutically.
This polyclonal knockout cell product is ideally suited for a wide array of research applications, including metabolic disorder modeling, investigation of cancer cell metabolism, and drug screening for mitochondrial encephalopathies such as ECHS1 deficiency and Leigh syndrome. Researchers can perform functional assays such as fatty acid oxidation flux measurements using radiolabeled palmitate or octanoate, ATP bioluminescence assays, Seahorse mitochondrial respiration analysis, and LC-MS-based metabolomics profiling of acyl-carnitines. Phenotypic assays under nutrient stress, including glucose deprivation or oxidative stress inducers, can reveal ECHS1-dependent survival mechanisms. Additionally, Western blotting and RT-qPCR confirm ECHS1 knockdown, while viability and proliferation assays enable high-throughput screening. For further details and ordering information, please contact Ascent Research.
